4basebio PLC held its Annual General Meeting, where all proposed resolutions were passed. Additionally, Hansjörg Plaggemars, a non-executive director, has stepped down from the board due to other business commitments. The company expressed gratitude for his contributions and wished him well in his future endeavors. 4basebio also highlighted an upcoming investor meeting on July 2, 2024, through the Investor Meet Company platform. This meeting aims to provide further insights into the company's developments and future plans.
4basebio is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The company aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for efficient payload delivery in patients.